Search

Displaying results 5821 - 5830 of 10000 in total
  1. Drug

    Tilmanocept

    go.drugbank.com/drugs/DB15373
    ApprovedInvestigationalWithdrawn

    Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed

  2. Drug

    Sabatolimab

    go.drugbank.com/drugs/DB16322
    Investigational

    Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic

  3. Drug

    Human growth hormone-releasing peptide 3

    go.drugbank.com/drugs/DB19227
    Investigational

    Human growth hormone-releasing peptide 3 is under investigation in clinical trial NCT00846872 (Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance

  4. Drug

    LIC-477

    go.drugbank.com/drugs/DB05363
    Experimental

    LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.

  5. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    It's mechanism of action is to inhibit c-Fos/activator protein-1.

  6. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). … In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.

  7. Drug

    ONO-2952

    go.drugbank.com/drugs/DB14802
    Investigational

    ONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable

  8. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    It received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.

  9. Drug

    RD06-04

    go.drugbank.com/drugs/DB24647
    Investigational

    RD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV).

  10. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small … [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections.